Literature DB >> 30674654

Rapamycin and Alzheimer's disease: Time for a clinical trial?

Matt Kaeberlein1, Veronica Galvan2,3.   

Abstract

The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30674654      PMCID： PMC6762017          DOI： 10.1126/scitranslmed.aar4289

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  38 in total

Review 1.  Antiaging Therapies, Cognitive Impairment, and Dementia.

Authors:  Devin Wahl; Rozalyn M Anderson; David G Le Couteur
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-09-16       Impact factor: 6.053

2.  Commentary: rapamycin for the aging skin.

Authors:  Christian Sell
Journal:  Geroscience       Date:  2020-03-29       Impact factor: 7.713

Review 3.  Crosstalk between the mTOR and Nrf2/ARE signaling pathways as a target in the improvement of long-term potentiation.

Authors:  Artem P Gureev; Vasily N Popov; Anatoly A Starkov
Journal:  Exp Neurol       Date:  2020-03-10       Impact factor: 5.330

4.  Rapamycin and Alzheimer disease: a double-edged sword?

Authors:  Julian M Carosi; Timothy J Sargeant
Journal:  Autophagy       Date:  2019-05-22       Impact factor: 16.016

Review 5.  mTOR at the nexus of nutrition, growth, ageing and disease.

Authors:  Grace Y Liu; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2020-01-14       Impact factor: 94.444

Review 6.  Effect of rapamycin on aging and age-related diseases-past and future.

Authors:  Ramasamy Selvarani; Sabira Mohammed; Arlan Richardson
Journal:  Geroscience       Date:  2020-10-10       Impact factor: 7.713

Review 7.  Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease.

Authors:  Tamas Fulop; Shreyansh Tripathi; Serafim Rodrigues; Mathieu Desroches; Ton Bunt; Arnold Eiser; Francois Bernier; Pascale B Beauregard; Annelise E Barron; Abdelouahed Khalil; Adam Plotka; Katsuiku Hirokawa; Anis Larbi; Christian Bocti; Benoit Laurent; Eric H Frost; Jacek M Witkowski
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-04       Impact factor: 2.570

Review 8.  Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes.

Authors:  Gabriela Dumitrita Stanciu; Razvan Nicolae Rusu; Veronica Bild; Leontina Elena Filipiuc; Bogdan-Ionel Tamba; Daniela Carmen Ababei
Journal:  Biomedicines       Date:  2021-05-19

Review 9.  Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.

Authors:  Henry Querfurth; Han-Kyu Lee
Journal:  Mol Neurodegener       Date:  2021-07-02       Impact factor: 14.195

10.  Reasons for Exclusion of Apparently Healthy Mature Adult and Senior Dogs From a Clinical Trial.

Authors:  Nicole H Gibbs; Hannah Michalski; Daniel E L Promislow; Matt Kaeberlein; Kate E Creevy
Journal:  Front Vet Sci       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.